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Summary Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial
cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two long-
established (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B,
UT-EC-3) using the 96-well-plate clonogenic assay. This assay has proven to be suitable for testing chemosen-
sitivity of both adenocarcinoma and squamous cell carcinoma. The chemosensitivity was expressed as an ICso
value, the drug concentration causing 50% inhibition of clonogenic survival. IC5, values were obtained from
dose-response curves after fitting the data by the linear quadratic equation, F = exp[-(aD + PD2)]. The IC,,
values of the two platinum derivatives varied considerably. The values for cisplatin varied between
0.0221g ml-' and 0.56 jug ml' and the corresponding values for carboplatin were 0.096-1.201g ml-'. The
range of the ratios between carboplatin IC50 and cisplatin IC50, from 1.5:1 to 4.4:1, was rather narrow.
However, no constant ratio between carboplatin IC5, and cisplatin IC50 could be detected. The equivalent
doses with regard to efficacy of these two platinum analogues remain to be determined.
The first platinum-containing drug, cisplatin, was introduced
to clinical use in the 1970s. It is widely used in the treatment
of solid malignancies, including tumours of the female genital
tract. Cisplatin is highly toxic, with nephrotoxicity and
neuropathy being the dose-limiting effects. The second-
generation drug, carboplatin, was developed in the 1980s
mainly to reduce side-effects. Carboplatin has low nephrotox-
icity and its major toxic effect is myelosuppression including
leucopenia and thrombocytopenia. Cisplatin and carboplatin
have also been studied for their ability to function as
radiosensitisers both in vitro and in vivo (Dewit 1987;
Pekkola-Heino et al., 1992a; Nguyen et al., 1993). Further-
more, promising clinical results of concomitant use of radia-
tion and platinum derivates have been obtained, especially in
the treatment of head and neck cancers (Jacobs et al., 1989;
Choi et al., 1991).
In the treatment of endometrial carcinoma chemotherapy
is used in advanced or recurrent cases. The treatment
schedules consist of 1-3 drugs, and platinum derivatives are
used either as single agents or as a part of a combined
chemotherapy regimen. When cisplatin is used as single-agent
therapy for advanced or recurrent endometrial carcinoma
response rates of 4-42% have been reported (Thigpen et al.,
1987). Total response rates of 33-47% have been achieved
using the combination of cisplatin, doxorubicin and cyc-
lophosphamide (Hoffman et al., 1989; Dunton et al.,
1991).
In vitro studies on the chemosensitivity of endometrial
cancer are scanty. In addition, comparative evaluations are
random; some of the published studies include cisplatin, but
not carboplatin (Jones et al., 1987; Nguyen et al., 1991).
Experiments with animals have shown high platinum concen-
trations in the uterus after intravenous administration (Lit-
ters et al., 1976, 1977). Recent clinical experience with
advanced cervical carcinoma suggests a positive correlation
between responses to chemotherapy and radiotherapy (Kirs-
ten et al., 1987). Also, in vitro studies performed with cervical
cancer cell lines support this clinical finding (Kelland &
Tonkin, 1989). The purpose of this study was to determine
the sensitivity of eight endometrial adenocarcinoma cell lines
to cisplatin and carboplatin and to correlate these findings
with the greatly variable intrinsic radiosensitivity of the cells.
Materials and methods
Cell lines
Eight endometrial adenocarcinoma cell lines were tested in
this study. The long-established endometrial cancer cell lines
RL95-2 and KLE were obtained from the American Type
Culture Collection (Rockville, MD, USA). Three cell lines
(UM-EC-1, UM-EC-2, UM-EC-3) have been established
recently under the supervision of T.E. Carey at the Univer-
sity of Michigan, and three cell lines (UT-EC-2A, UT-EC-
2B, UT-EC-3) at the University of Turku by one of us
(S.G.). The cell lines used, their histological type and grade,
the in vitro doubling time, passages used, their plating
efficiencies (PE) and the references are listed in Table I. The
KLE cell line was derived from a metastatic intra-abdominal
tumour. The donor had received both chemotherapy and
hormonal therapy preoperatively. The chemotherapy regimen
did not contain platinum analogues. The UT-EC-2A cell line
was established from primary endometrial tumour, and the
UT-EC-2B cell line was derived from the same patient from a
supraclavicular metastasis 17 months later. The patient had
received radiotherapy to the site of the primary tumour and
six courses of combined chemotherapy containing cisplatin
and hormonal therapy with medroxyprogesterone acetate
before the detection of the supraclavicular metastasis (Ran-
tanen et al., 1993a). The other cell lines were established
from primary tumours before any treatments.
Cell culture
Prior to the experiments the cells were maintained in
logarithmic growth in T25 culture flasks by passing weekly
in Dulbecco's modified Eagle minimal essential medium
(DMEM) containing 2 mM L-glutamine, 1% non-essential
amino acids, 100 U ml-' penicillin, 100 U ml-' streptomycin
and 10% fetal bovine serum (FBS). Cells in mid-logarithmic
growth (40-60% confluency) were used for experiments and
fed with fresh medium on the day before plating.
Drugpreparation
Cisplatin (Platinol) 0.5 mg ml-' was diluted with growth
medium to get a stock solution 100 fig ml-' and sterilised by
pressing through a 0.22 tLm filter. Final cisplatin dilutions of
0.02-2.0 g ml-' were used, and new stock solutions were
made for each experiment.
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Table I The cell lines used, their histological type and grade, the in vitro doubling time, passages used, the plating
efficiencies (PE) and the references
Histological type In vitro Passages Plating
Cell line and grade doubling time (h) used efficiency (PE) Reference
RL95-2 Adenosquamous 22 152-162 0.32-0.80 Way et al. (1983)
carcinoma, 2
KLE Adenocarcinoma, 3 104 26-38 0.013-0.059 Richardson et al.
(1984)
UM-EC-1 Adenocarcinoma, 3 24 13-27 0.08-0.48 Grenman et al.
(1988a)
UM-EC-2 Adenocarcinoma, 3 36 6-42 0.036-0.094 Grenman et al.
(1990)




UT-EC-2A Adenosquamous 40 12-45 0.031-0.44 Rantanen et al.
carcinoma, 2 (1993a)
UT-EC-2B Adenosquamous 30 8-39 0.09-0.44 Rantanen et al.
carcinoma, 2 (1993a)
UT-EC-3 Adenocarcinoma, 3 28 28-40 0.076-0.30 Rantanen et al.
(1993b)
aUnder characterisation (S. Grenman).
Carboplatin (Paraplatin) was dissolved in growth medium
as a stock solution of 100 Ltg ml-' and sterilised by pressing
through a 0.22 tLm filter. The final dilutions 0.05-2.5 sgml-'
were made immediately before use, and new stock solutions
were made for each experiment.
Clonogenic assay
The 96-well clonogenic assay based on limiting dilutions was
used. The assay has been described earlier in detail (Grenman
et al., 1989; Rantanen et al., 1993b). A minimum of three
experiments including duplicate plates were performed for
each cell line. The cells were harvested with trypsin-EDTA
to obtain a single-cell suspension, counted and diluted in
Ham's F-12 medium containing 15% fetal bovine serum
(FBS) or newborn bovine serum (NBS). With a cell suspen-
sion containing 4,167 cells ml-' and diluted in 25 ml of
growth medium, a concentration of two cells per well is
achieved by applying 100ftl to each well with an octapipette
(Costar). The number of cells plated per well was adjusted
according to the plating efficiency (PE) of the cell line. After
plating into the 96-well plate the cells were allowed to attach
for 24 h at 37°C in an incubator with a water vapour-
saturated atmosphere containing 5% carbon dioxide.
Twenty-four hours after plating, 100#l of growth medium
containing the desired concentration of cisplatin or carbo-
platin was added to the wells.
To obtain dose-response curves for cisplatin and carbo-
platin, the drug solutions were allowed to remain in the
plates during the whole incubation period. The plates were
kept in the incubator for 4 weeks, after which time the
number of wells containing coherent, living colonies (a col-
ony consisting of 32 cells or more) was counted using an
inverted phase-contrast microscope.
Data analysis
Plating efficiency (PE) was calculated using the formula
PE = - In (number of negative wells/total number of wells)/
number of cells plated per well (Thilly et al., 1980). The
fraction survival data as a function of the cisplatin or car-
boplatin dose were fitted by linear quadratic equation. A
microcomputer program was used to fit data F= exp
[-(aD + PD2)]. The comparison of drug sensitivity was made
using IC50 values (50% inhibition of surviving fraction),
which were obtained from the fitted dose-response curves.
Results
The PE values of the cell lines are listed in Table I. Dose-
response curves for each cell line were obtained by fitting the
data points to the linear quadratic equation (Figure la-h).
The IC50 values of the cell lines obtained from the cisplatin
and carboplatin dose-response curves are given in Table II.
IC_, values for cisplatin varied between 0.022figmlm' and
0.56;Lgml-', and IC50 values for carboplatin between
0.0961agml-' and 1.20fgmm1'. The mean IC50 values for
cisplatin and carboplatin were 0.23jgml' and 0.50isgml
respectively.
The IC50 values for carboplatin were mostly higher than
the corresponding values for cisplatin. The only exception
was the UM-EC-2 cell line, which had an IC50 value of
0.19 ,gml-' for cisplatin and 0.16 Lg ml-l for carboplatin.
The range of the ratios between carboplatin IC50 and cis-
platin IC50, 1.5:1 to 4.1:1, was rather narrow, but no con-
stant ratio between these values could be noticed. The sen-
sitivity for both platinum analogues varied considerably
between individual cell lines. The correlation between IC50
values for cisplatin and carboplatin and the inherent radio-
sensitivity of the cell lines were estimated by Pearson correla-
tion. No correlation could be demonstrated comparing the
results from the current study with the radiosensitivity of the
same cell lines tested earlier (Rantanen et al., 1992, 1993a,
b).
Discussion
In vitro data on the chemosensitivity of endometrial cancer
are scanty partly because of the lack of suitable cell lines. We
have recently established and characterised numerous
endometrial adenocarcinoma cell lines (Grenman et al., 1988b,
1990) and used them for testing in vitro radiosensitivity of
this tumout type (Rantanen et al., 1992, 1993a, b). These
studies have been performed using the 96-well-plate
clonogenic assay, which has proven to be suitable for testing
both radiosensitivity and chemosensitivity ofadenocarcinoma
as well as squamous cell carcinoma cell lines (Grenman et al.,
1988a, 1989, 1991; Pekkola-Heino et al., 1989, 1991, 1992a,
b; Rantanen et al., 1992, 1993a, b). In this study we tested
the chemosensitivity ofeight endometrial cancer cell lines and
demonstrated considerable variability between individual cell
lines.
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Figure 1 Sensitivity of eight endometrial adenocarcinoma cell lines for cisplatin (0) and carboplatin (0). The figures show the
fraction survival curves as a function of cisplatin and carboplatin dose. The results are given as the average of the actual data
points and the bars represent 0.5 s.d. The data were fitted by a linear quadratic equation to produce the fraction survival curves. a,
RL95-2; b, KLE; c, UM-EC-1; d, UM-EC-2; e, UM-EC-3; f, UT-EC-2A; g, UT-EC-2B; h, UT-EC-3.
The cytotoxic effects of cisplatin and carboplatin were
compared in a variety of cell lines, including ovarian car-
cinoma cell lines (Hills et al., 1989; Fanning et al., 1990;
Dittrich et al., 1993) and stomach and lung cancer cell lines
(Takahashi et al., 1987). The results obtained from in vitro
chemosensitivity testing vary considerably and because of
different methods and exposure times they cannot be directly
compared. Jones et al. (1987) determined the chemosen-
sitivities of fresh human endometrial tumour samples with a
soft-agar clonogenic assay. They used continuous drug
exposure and achievable peak plasma levels (2.5 l.g ml-') and
one-tenth peak plasma levels (0.25 jg ml-'). Twenty-seven of
30 endometrial adenocarcinoma samples demonstrated 70%
or more reduction in colony formation with peak plasma
level of cisplatin, and the corresponding number for one-
tenth peak plasma level was 10 out of 21. Nguyen et al.
(1991) evaluated the chemosensitivity of uterine cancer cell
lines using ATP bioluminescence assay and 90 min exposure
to cisplatin or carboplatin. IC50 values for carboplatin were
higher in three cases (x 1.1-2.1) and IC50 values for cisplatin
were higher in three cases (x 1.3-10.0).
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Table II Chemosensitivity ofeight endometrial adenocarcinoma cell
lines to cisplatin and carboplatin expressed as ICn values
(concentration causing 50% inhibition of clonogenic survival)
Cisplatin Carboplatin
Cell line ICjo± s.d. (figml-') IC50 ± s.d. (1gml-')
RL95-2 0.43 ± 0.13 1.20 ± 0.07
KLE 0.022 ± 0.003 0.096 ± 0.009
UM-EC-1 0.31 + 0.10 0.46 ± 0.16
UM-EC-2 0.19 ± 0.08 0.16 + 0.03
UM-EC-3 0.13 ± 0.05 0.27 ± 0.12
UT-EC-2A 0.15 ± 0.07 0.63 i 0.15
UT-EC-2B 0.56 ± 0.06 1.06 ± 0.35
UT-EC-3 0.034 ± 0.005 0.10 + 0.03
endometrial adenocarcinoma cell lines for both cisplatin and
carboplatin. The IC50 for cisplatin varied from 0.022fig ml1-
to 0.56fig ml'. There was a 25-fold difference between the
most resistant and the most sensitive cell line. This finding is
consistent with the results of Hills et al. (1989) obtained from
testing ovarian cancer cell lines. The IC50 values for carbo-
platin varied from 0.096 tLg ml-I to 1.20jigmlh'. The differ-
ence between the most resistant and the most sensitive cell
line was 12-fold. The capacity to cause cell death in vitro is
lower for a given dose for carboplatin than for cisplatin. In
this study the mean IC50 values were 0.23 igml-1 for cisp-
latin and 0.50 lg ml1' for carboplatin. The ratio of carbo-
platin ICso to cisplatin ICso varied in our material from 1.5:1
to 4.4:1. These data fit with the current clinical practice of
using carboplatin and cisplatin in the ratio of 3-4:1. How-
ever, Terheggen et al. (1988, 1991) reported that on a molar
basis 6-18 times more carboplatin than cisplatin is required
to obtain the same level of DNA and platinum interaction
products in cancer patients. Their in vitro studies indicated a
direct correlation between cisplatin- and carboplatin-induced
cell kill and DNA adduct production (Terheggen et al.,
1990). The predictive value ofDNA adduct production is still
unevaluated, and further clinical studies are needed to
confirm the equivalent clinical doses with regard to efficacy
of these two platinum analogues.
In our results the difference between UT-EC-2A and UT-
EC-2B IC50 values for cisplatin and carboplatin is of interest.
The UT-EC-2A cell line was established from the primary
tumour and the UT-EC-2B cell line was established from a
supraclavicular metastasis after the donor had received six
courses of chemotherapy including cisplatin. Cisplatin-
induced growth inhibition was remarkable in UT-EC-2A cul-
tures, whereas the UT-EC-2B cell line was the most resistant
cell line to cisplatin. UT-EC-2B cells were also found to be
highly resistant to carboplatin. These findings could be
explained by selection of platinum-resistant cells in the
donor's tumour during treatment with platinum-containing
chemotherapy.
Results obtained by Kelland and Tonkin (1989) suggest a
positive correlation between the chemo- and radiosensitivity
of squamous cell carcinoma lines of the uterine cervix. Fur-
thermore, a positive correlation between response to
chemotherapy and subsequent response to radiotherapy has
been reported in a group of patients with locally advanced
cervical cancer (Kirsten et al., 1987). We have previously
tested the radiosensitivity of the endometrial cancer cell lines
used in this study (Rantanen et al., 1992, 1993a, b).
Therefore, it was of interest to compare the chemosensitivity
and radiosensitivity of individual cell lines. We could not find
a correlation between cisplatin and carboplatin sensitivities
and the intrinsic radiation sensitivity of the eight endometrial
cancer cell lines.
Concomitant use of radiation and chemotherapy in the
treatment of radioresistant tumours is one possibility to
achieve better outcome in these patients. Owing to the wide-
spread clinical use of platinum analogues in the treatment of
advanced or recurrent endometrial cancer, it seems logical to
evaluate their use also as radiosensitisers. Before planning
schedules for chemoradiotherapy it is important to know the
in vitro sensitivities of the drugs used for the tumour type in
question. Without basic knowledge obtained from in vitro
studies it is difficult to determine optimal doses and timing
between radiation and the exposure to chemotherapeutic
agent.
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